SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 8, 2019--
Tricida, Inc. (Nasdaq: TCDA) today announced the closing of its
previously announced public offering of 6,440,000 shares of its common
stock at a public offering price of $36.00 per share, which includes the
exercise in full by the underwriters of their option to purchase 840,000
additional shares of common stock for total gross proceeds of
approximately $231.8 million, before deducting underwriting discounts
and commissions and other offering expenses payable by Tricida.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and
Company, LLC acted as joint book-running managers for the offering.
Needham & Company, LLC acted as co-manager.
Registration statements relating to these securities have been filed
with the U.S. Securities and Exchange Commission and became effective
under the Securities Act of 1933, as amended, on April 3, 2019. The
offering was made only by means of a prospectus, copies of which may be
obtained from: Goldman Sachs & Co. LLC, Prospectus Department, 200 West
Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile:
212-902-9316 or by emailing firstname.lastname@example.org;
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204, or by
or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, telephone: 631-274-2806, or
This press release does not constitute an offer to sell or a
solicitation of an offer to buy securities, nor shall there be any sale
of such securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
Tricida, Inc. is a pharmaceutical company focused on the development and
commercialization of its drug candidate, TRC101 (veverimer), a
non-absorbed, orally-administered polymer designed to treat metabolic
acidosis in patients with chronic kidney disease (CKD) by binding and
removing acid from the gastrointestinal tract.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190408005732/en/
Source: Tricida, Inc.
Jackie Cossmon, IRC
Vice President of Investor
Relations and Communications